Behold.ai vs Qure AI (2026)
Two chest radiograph companies separated by whether a person still looks at every film. Behold auto reports films it classifies as high confidence normal, removing them from the worklist, which is autonomy inside a bounded task, and its confidence threshold is the governance mechanism. Qure's US clearances are reading aids and triage devices, with qXR-Detect cleared in January 2026 as a concurrent reading aid for six categories of chest X-ray findings. Qure also markets sorting out unremarkable chest X-rays, citing a 99 percent negative predictive value from a service evaluation, and does not say who reads the studies it sets aside. That use is outside its US clearances. The evidence bar follows the autonomy. A product that sets studies aside needs its false negative rate at the operating threshold published and revalidated locally, because a missed finding on a film nobody reads is never seen.
- It removes studies from the worklist, classifying chest radiographs as high confidence normal and auto reporting them, autonomy inside a deliberately bounded task.
- The performance numbers that matter for that autonomy are published in peer reviewed venues, and the confidence threshold is the governance mechanism.
- For a service drowning in normal chest films, removing them from the queue is a different economic proposition from reading them faster.
- Cleared reading aids that keep the radiologist on the read: qXR-Detect as a concurrent aid and qXR-LN as a second reader for lung nodules.
- A cleared change plan for qXR-Detect, setting out how the model can be updated and how users are told.
- Tuberculosis screening evidence from independent studies in several countries and a 2025 systematic review.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Behold.ai and Qure AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
UK company whose red dot platform sits at the autonomous end of imaging AI: it reports chest X-rays it classifies as High Confidence Normal autonomously, removing them from the radiologist worklist (about 15 percent of studies, according to the company), triages suspected lung cancer for urgent reporting, and has a companion CT head product. Work published in Clinical Radiology reported a 0.33 percent error rate on the auto reported studies and a 60 percent reduction in missed lung cancers when triage ran alongside consultant radiologists.
Source: AI Health Index, August 2026
Qure.ai, founded in 2016 in Mumbai with a US entity in New York, sells radiology AI in more than 105 countries through more than 5,500 sites by its own count. Its products are qXR for chest X-ray (detection, reporting, lung nodules and tuberculosis screening), qER for head CT in stroke and trauma, qCT for chest CT nodules and lung cancer, qMSK for musculoskeletal X-ray, and heart failure detection.
Source: AI Health Index, August 2026
Questions buyers ask
How do Behold.ai and Qure AI work with the EHR?
For Behold.ai, the how it works page states that after analysis it sends an electronic notification back to the trust RIS, or to PACS where reporting is PACS driven, marking each examination as normal or abnormal and prioritizing it in the existing worklist; for auto reported studies that notification is the report.
With Qure AI, the qXR page promises zero integration effort and deployment on cloud or on premise, the company says its software works with new and old X-ray systems, and the qXR-Detect summary describes results returned to radiology software or the X-ray console; qXR-LN is cleared for use with any DICOM viewer or PACS. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How are Behold.ai and Qure AI priced and sold?
In Behold.ai's case, the original company entered administration in January 2025 after failing to win NHS AI Diagnostic Fund contracts, NICE withdrew the product from its recommendations the following month, and a successor acquired the assets and relaunched it.
For Qure AI, the portfolio makes the gap matter. Qure sells chest X-ray, head and chest CT and musculoskeletal products under ten US clearances, plus tuberculosis care cascades and the Aira care delivery platform, and nothing says whether indications are licensed singly, bundled by modality or sold as a platform. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How do Behold.ai and Qure AI handle patient data?
With Behold.ai, the how it works page states that images reach the platform over an encrypted VPN and that all patient examination data resides in fully NHS accredited data centers.
Qure's Security and Regulatory page says data is de-identified before it leaves a covered entity's premises for cloud processing, and that on-premise installations may process identifiable images only on servers the customer owns and operates. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Which settings and specialties do Behold.ai and Qure AI cover?
For Behold.ai, the settings on record are NHS trust radiology departments.
Qure covers chest X-ray, head and chest CT and musculoskeletal X-ray, sold to hospitals, imaging centers, teleradiology services, immigration screening and public health programs in more than 105 countries. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Behold's record has not yet been reviewed on this site, so its side of this page rests on the build record. Its regulatory standing spans several jurisdictions and is unsettled, and its corporate history complicates the identity of the contracting entity; establish both before deployment.
Both now touch the same question from different sides. Behold's autonomy is its product; Qure's normal segregation is a marketed use with no published routing. Ask each for the false negative rate at the threshold it runs, and who, if anyone, reads what it sets aside. Neither publishes pricing.